Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.

ABSTRACT:

Background

Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design.

Methods

Adult volunteers aged 18-59 years were recruited at five geographically distinct communities in South Africa. Whole blood was sampled for RISK11 by quantitative RT-PCR assay from eligible volunteers without HIV, recent previous tuberculosis (ie, <3 years before screening), or comorbidities at screening. RISK11-positive participants were block randomised (1:2; block size 15) to once-weekly, directly-observed, open-label isoniazid and rifap

SUBMITTER: Scriba TJ 

PROVIDER: S-EPMC7907670 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature